Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021

touchCONGRESS for touchONCOLOGY Listen to Prof. Edward Garon (USA) cover key data presented at ASCO and ESMO 2021 on optimizing frontline immunotherapy for advanced NSCLC, including expert insights and interpretation from Dr Raffaele Califano (UK) and Prof. Anne-Marie Dingemans (The Netherlands). OVERVIEW Data review with Prof. Garon (0:00) Expert interview with Dr Califano, Prof. Dingemans and Prof. Garon, answering the questions below INTERVIEW QUESTIONS Based on data recently presented at ASCO21 and ESMO 2021, how do you think new and emerging immunotherapy (IO) agents will impact the frontline treatment landscape in advanced NSCLC? (36:02) How can key learnings from ASCO21 and ESMO 2021 be integrated into clinical practice when choosing between available IO-based regimens (e.g. IO monotherapy, IO combination therapy, and/or in addition to chemotherapy)? (43:32) How is our understanding of the role of PD-L1 as a biomarker in NSCLC evolving in light of recent data, and what are the possible implications for clinical practice? (48:11) What unmet needs remain surrounding biomarkers beyond PD-L1 in NSCLC, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:12) What have the latest data, including patient-reported outcomes, taught us regarding the optimal management of patients receiving frontline immunotherapy for advanced NSCLC? (57:06) This touchPODCAST is for HCPs only.  This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/optimizing-frontline-immunotherapy-for-advanced-nsclc/